1. Home
  2. NRIX vs THRM Comparison

NRIX vs THRM Comparison

Compare NRIX & THRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRIX
  • THRM
  • Stock Information
  • Founded
  • NRIX 2009
  • THRM 1991
  • Country
  • NRIX United States
  • THRM United States
  • Employees
  • NRIX N/A
  • THRM N/A
  • Industry
  • NRIX Biotechnology: Pharmaceutical Preparations
  • THRM Auto Parts:O.E.M.
  • Sector
  • NRIX Health Care
  • THRM Consumer Discretionary
  • Exchange
  • NRIX Nasdaq
  • THRM Nasdaq
  • Market Cap
  • NRIX 952.9M
  • THRM 1.0B
  • IPO Year
  • NRIX 2020
  • THRM 1993
  • Fundamental
  • Price
  • NRIX $11.49
  • THRM $27.60
  • Analyst Decision
  • NRIX Strong Buy
  • THRM Buy
  • Analyst Count
  • NRIX 16
  • THRM 3
  • Target Price
  • NRIX $30.44
  • THRM $48.00
  • AVG Volume (30 Days)
  • NRIX 796.7K
  • THRM 238.1K
  • Earning Date
  • NRIX 07-10-2025
  • THRM 07-30-2025
  • Dividend Yield
  • NRIX N/A
  • THRM N/A
  • EPS Growth
  • NRIX N/A
  • THRM 10.20
  • EPS
  • NRIX N/A
  • THRM 1.59
  • Revenue
  • NRIX $56,417,000.00
  • THRM $1,453,963,000.00
  • Revenue This Year
  • NRIX $16.69
  • THRM N/A
  • Revenue Next Year
  • NRIX N/A
  • THRM $4.04
  • P/E Ratio
  • NRIX N/A
  • THRM $17.29
  • Revenue Growth
  • NRIX N/A
  • THRM N/A
  • 52 Week Low
  • NRIX $8.18
  • THRM $22.75
  • 52 Week High
  • NRIX $29.56
  • THRM $56.68
  • Technical
  • Relative Strength Index (RSI)
  • NRIX 50.78
  • THRM 51.56
  • Support Level
  • NRIX $12.25
  • THRM $27.24
  • Resistance Level
  • NRIX $12.00
  • THRM $28.27
  • Average True Range (ATR)
  • NRIX 0.69
  • THRM 0.88
  • MACD
  • NRIX -0.08
  • THRM -0.04
  • Stochastic Oscillator
  • NRIX 21.57
  • THRM 56.44

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About THRM Gentherm Inc

Gentherm Inc is an automotive parts manufacturer. The business activities of the group function through the Automotive and Medical segments. The vast majority of the firm's revenue comes from the Automotive segment, which includes automotive climate comfort systems, automotive cable systems, battery performance solutions, and automotive electronics and software systems. The medical segment is comprised of the results from the patient temperature management business in the medical industry. Its geographical segments are the United States, China, South Korea, Germany, Japan, the Czech Republic, and other countries.

Share on Social Networks: